Request Demo

Last update 08 May 2025

endometrial clear cell carcinoma

Last update 08 May 2025

Basic Info

Synonyms

Clear Cell Carcinoma of Endometrium, Clear Cell Carcinoma of the Endometrium, Clear cell endometrial carcinoma

+ [10]

Introduction

A high-grade endometrial adenocarcinoma characterized by the presence of large neoplastic cells that display at least focal cytoplasmic clearing. The neoplastic cells form papillary, glandular, or sheet-like structures.

Drugs associated with endometrial clear cell carcinoma

Mirvetuximab soravtansine

Target

FOLR1 x Tubulin

Mechanism

FOLR1 antagonists [+1]

Active Org.

AbbVie, Inc. [+5]

Originator Org.

ImmunoGen, Inc.

Active Indication

Folate receptor-alpha positive, platinumresistant epithelial ovarian cancer [+22]

Inactive Indication

endometrial clear cell carcinoma [+5]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date14 Nov 2022

Selumetinib sulfate

Target

MEK1 x MEK2

Mechanism

MEK1 inhibitors [+1]

Active Org.

AstraZeneca UK Ltd. [+11]

Originator Org.

Array BioPharma, Inc.

Active Indication

Neurofibromatoses [+64]

Inactive Indication

Acute Promyelocytic Leukemia [+68]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date10 Apr 2020

Nintedanib esylate

Target

CSF-1R x FGFRs x FLT3 x PDGFRs x VEGFR

Mechanism

CSF-1R antagonists [+4]

Active Org.

Boehringer Ingelheim GmbH [+16]

Originator Org.

Boehringer Ingelheim International GmbH

Active Indication

Locally Advanced Lung Non-Small Cell Carcinoma [+26]

Inactive Indication

Adenocarcinoma of large intestine [+48]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date15 Oct 2014

Clinical Trials associated with endometrial clear cell carcinoma

NCT06638931

/ RecruitingPhase 2IIT

Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors

The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and treatment will last for up to 12 months. The study will assess objective response, progression-free survival, and biomarkers such as PD-L1, ctDNA, and microvesicles, in a multicenter collaborative effort to provide innovative therapeutic options for this underrepresented population

Start Date01 Jul 2024

Sponsor / Collaborator

Instituto do Cancer do Estado de Sao Paulo

[+1]

NCT05289648

/ WithdrawnEarly Phase 1IIT

The Molecular and the Clinical Effects of Preoperative Niraparib in Patients with High-grade Endometrial Cancer: Phase 0 Exploratory Trial

The study will investigate the effect of niraparib on tumor tissue in chemotherapy naïve, newly diagnosed, high-grade endometrial cancer patients. Biomarkers of cognate molecular pathways as well as investigational assays will be used to study the antineoplastic effect of the drug.

Start Date01 May 2024

Sponsor / Collaborator

The Jewish General Hospital

NCT05950464

/ RecruitingPhase 1IIT

A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer

This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent). M1774 and ZEN-3694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. M1774 and ZEN-3694 combined together has demonstrated to be better than either drug alone in killing ovarian tumor cells.

Start Date18 Dec 2023

Sponsor / Collaborator

National Cancer Institute

[+1]

100 Clinical Results associated with endometrial clear cell carcinoma

100 Translational Medicine associated with endometrial clear cell carcinoma

0 Patents (Medical) associated with endometrial clear cell carcinoma

261

Literatures (Medical) associated with endometrial clear cell carcinoma

01 May 2025·Gynecologic Oncology

Adjuvant treatment in stage I clear cell endometrial carcinoma: A population-based study of survival outcomes

Article

Author: Chang, Jenny ; Tseng, Jill ; Greenberg, Danielle ; Bujnak, Alyssa C

OBJECTIVEUterine clear cell carcinoma (UCCC) is a rare but aggressive histologic type of endometrial cancer. Recommendations for adjuvant treatment of early-stage UCCC remain vague. The objective of this study is to assess the impact of adjuvant treatment on survival outcomes of patients with stage I UCCC.METHODSUsing the Surveillance, Epidemiology and End Results database (SEER), patients with stage I UCCC were identified. Disease-specific survival (DSS) as well as overall survival (OS) for patients who underwent observation alone versus adjuvant treatment with either chemotherapy alone, radiotherapy (RT) alone, or chemotherapy plus RT, were analyzed by Kaplan-Meier (K-M) survival estimates and multivariate Cox proportion hazards model.RESULTSThe study included 881 patients with stage I UCCC. Kaplan-Meier estimates showed no difference in DSS among those who underwent observation versus adjuvant treatment. In the multivariate model for DSS, tumor size ≥40 mm was associated with an increased risk of death (HR 2.02, p = 0.0267) while living in a metropolitan county decreased the risk of death (HR 0.46, p = 0.009). The K-M curve for OS showed a significant difference among the four treatment groups (p = 0.0475), with a 10-year OS of 61 % for patients who received no adjuvant treatment versus 74 % for those receiving chemotherapy plus radiation. However, this difference was not significant in the multivariate analysis.CONCLUSIONSIn this study of stage I UCCC, the use of adjuvant treatment did not confer a survival advantage. Observation may be considered an acceptable option although prospective research is needed.

01 Apr 2025·International Journal of Surgical Pathology

Endometrial Clear Cell Carcinoma with Non-Gestational Uterine Choriocarcinoma Differentiation

Article

Author: Api, Murat ; Yeni Erdem, Begum ; Kara, Sahra Sultan ; Keles, Esra

Choriocarcinoma is a rare and highly malignant tumor that primarily occurs in women of reproductive age. Choriocarcinoma can be classified as gestational or nongestational, based on its pathogenetic origin. Although primary nongestational choriocarcinoma has been described in the ovaries, it is very rare in the uterus, especially in postmenopausal women. It is crucial to differentiate between gestational and non-gestational choriocarcinoma, as it affects the choice of treatment and prognosis. Endometrial clear cell carcinoma is an aggressive subtype of endometrial cancer, accounting for less than 10% of all uterine carcinomas. Trophoblastic differentiation in uterine cancer is unusual and very rare, with only three examples of the subtype of clear cell endometrial cancer with gestational choriocarcinoma reported in the literature, including only one with nongestational choriocarcinoma. Here, we present an example of clear cell carcinoma with nongestational uterine choriocarcinoma differentiation in a postmenopausal woman.

01 Mar 2025·International Journal of Gynecological Cancer

Controversies in the management of clear cell carcinoma of the uterus and ovary

Review

Author: Tan, David ; Blanc-Durand, Felix ; Sachdeva, Manavi

Clear cell ovarian and endometrial carcinomas are rare and aggressive gynecologic malignancies that present unique challenges owing to their underrepresentation in clinical trials and limited prospective data. In this report, we aimed to explore 3 major controversies in the management of clear cell ovarian and endometrial carcinomas, highlighting areas that require further investigation. First, we addressed the unique phenotypic characteristics of clear cell ovarian carcinoma and clear cell endometrial carcinoma and whether they should be considered a unified disease entity or a distinct disease. Recent trials grouped these carcinomas, potentially expanding their therapeutic options. However, emerging molecular data underscores the significant differences between clear cell ovarian carcinoma and clear cell endometrial carcinoma, raising questions regarding this combined approach. This distinction is critical in guiding tailored treatment strategies. Second, we examined the management of localized diseases. Although early-stage diagnoses are common in clear cell carcinomas, optimal surgical and adjuvant treatment strategies remain uncertain. Current practice often relies on data from broader studies with limited inclusion of clear cell histology. This review underscores the need for more specific evidence to refine treatment protocols and balance efficacy with the minimization of treatment-related morbidity. Third, we explored novel therapeutic strategies for the treatment of recurrent diseases. Advances in the understanding of the biology of clear cell carcinomas have identified potential targets in the immune microenvironment, cellular processes, and metabolism. Ongoing clinical trials are investigating these approaches, which hold promise in transforming the treatment landscape and outcomes. In conclusion, this review emphasizes the necessity for international collaboration and the inclusion of diverse patient populations to address the challenges posed by cell carcinomas. By focusing on these controversies, we aim to stimulate further research and support more evidence-based personalized approaches for the management of these rare but challenging cancers.

Analysis

Perform a panoramic analysis of this field.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

endometrial clear cell carcinoma

Basic Info

Related

Analysis